Melatonin treatment for age-related insomnia

Area of Science:

• Gerontology
• Sleep Medicine
• Endocrinology

Background:

• Older adults often experience reduced sleep efficiency and lower nocturnal melatonin levels.
• Exogenous melatonin administration can improve sleep onset in younger individuals.

Purpose of the Study:

• To investigate the efficacy of physiological melatonin doses in improving sleep efficiency and restoring nocturnal melatonin levels in older insomniacs.
• To compare the effects of different melatonin doses (0.1, 0.3, and 3.0 mg) on sleep and melatonin profiles in individuals over 50 years old.

Main Methods:

• Double-blind, placebo-controlled study with randomized crossover design.
• Participants included normal sleepers and individuals with confirmed decreased sleep efficiency (n=15 each).
• Polysomnography was used to assess sleep on the final three nights of each weekly treatment period.

Main Results:

• A physiological dose of 0.3 mg melatonin significantly restored sleep efficiency (P < 0.0001) and normalized plasma melatonin levels (P < 0.0008) in older insomniacs.
• The 3.0 mg dose improved sleep but caused hypothermia and prolonged elevated melatonin levels into daylight.
• Neither melatonin nor placebo affected sleep in normal-sleeping control subjects, despite their low melatonin levels.

Conclusions:

• Physiological melatonin supplementation (0.3 mg) is effective in improving sleep efficiency in older adults with insomnia.
• Higher melatonin doses may lead to adverse effects, including prolonged melatonin elevation.
• Melatonin's efficacy may be specific to individuals with sleep disturbances and low endogenous melatonin.